BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients

BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients

Detalles Bibliográficos
Main Authors:	Kizilors, A, Jackson, S, Anwar, J, Sa, I, Ficinski, L, Mian, S, Best, S, Copland, M, Hassan, S, Mead, A, Ewing, J, Drummond, M, Papanikolaou, M, Ottmann, O, Thompson, M, Lea, N, De Lavallade, H
Formato:	Conference item
Publicado:	Wiley 2019

Títulos similares

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian Afsar, et al.
Publicado: (2012-09-01)

FISH mapping of Philadelphia negative <it>BCR/ABL1 </it>positive CML
por: Marin David, et al.
Publicado: (2008-07-01)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Camille C.B. Kockerols, et al.
Publicado: (2020-12-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
por: Aya Bonilla, Carlos Alberto, et al.
Publicado: (2014-10-01)

Quantification of Main Bcr-abl Gene Transcripts in CML Patients Using Competitive RT-PCR
por: Ali Nazemi, et al.
Publicado: (2016-04-01)

Quantification of main bcr-abl gene transcripts in CML patients using competitive RT-PCR
por: Ali Nazemi, et al.
Publicado: (2016-04-01)

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, N, et al.
Publicado: (2018)

The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
por: Anahita Rafiei, et al.
Publicado: (2015-04-01)

p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
por: Afsar A. Mian, et al.
Publicado: (2012-02-01)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
por: John M. Bennett, et al.
Publicado: (2015-01-01)

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
por: Lenka Hovorkova, et al.
Publicado: (2024-07-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Erin Clapper, et al.
Publicado: (2020-03-01)

Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
por: Shantashri Vaidya, et al.
Publicado: (2015-01-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Maria Stella Pennisi, et al.
Publicado: (2019-08-01)

ROLE OF BREAK CLUSTER REGION (BCR) - ABELSON MURINE LEUKIMIA (ABL) EXAMINATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
por: Agung Sosiawan
Publicado: (2015-07-01)

Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL
por: Margaret M. Mc Gee, et al.
Publicado: (2001-01-01)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
por: Daniela Zizioli, et al.
Publicado: (2021-02-01)

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients
por: Bakshi Sonal R., et al.
Publicado: (2009-01-01)

Targeting BCR-ABL1-positive leukaemias: a review article
por: Steven Leak, et al.
Publicado: (2023-01-01)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Kousuke Watanabe, et al.
Publicado: (2020-01-01)

PREDICTIVE VALUE OF QUANTITATIVE RT-QPCR BCR::ABL1 AT DIAGNOSIS AND EUTOS SCORE FOR IMATINIB RESPONSE IN CML PATIENTS
por: DS Oliveira, et al.
Publicado: (2024-10-01)

BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
por: Akhilesh S, et al.
Publicado: (2024-01-01)

ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
por: Zhiqiang Wang, et al.
Publicado: (2014-06-01)

Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
por: Maysaa A. Dhahii
Publicado: (2010-04-01)

Correction: ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
por: PLOS Genetics Staff
Publicado: (2015-03-01)

A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.
por: Tzu-Yi Yang, et al.
Publicado: (2013-01-01)

Genomic amplification of <it>BCR/ABL1 </it>and a region downstream of <it>ABL1 </it>in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
por: Virgili Anna, et al.
Publicado: (2010-09-01)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
por: Aleksandra Mroczkowska-Bękarciak, et al.
Publicado: (2023-09-01)

Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population
por: Jew Win Kuan, et al.
Publicado: (2024-06-01)

Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
por: Sudha Sazawal, et al.
Publicado: (2019-01-01)

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
por: Foroni, L, et al.
Publicado: (2011)

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
por: Berke, Z, et al.
Publicado: (2000)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Shohei Kawakami, et al.
Publicado: (2022-01-01)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
por: Maymona G. Abdelmagid, et al.
Publicado: (2022-07-01)

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia
por: Wulyo Rajabto, et al.
Publicado: (2018-03-01)

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
por: Ilaria Iacobucci, et al.
Publicado: (2007-03-01)

S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS
por: C. Kockerols, et al.
Publicado: (2022-06-01)

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels
por: Hana Klamová, et al.
Publicado: (2013-04-01)

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
por: Adcharee Kongruang, et al.
Publicado: (2023-12-01)

Mutant BCR-ABL clones in chronic myeloid leukemia
por: Michael S. Mathisen, et al.
Publicado: (2011-03-01)